Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
penicitrinone A
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
Penicitrinone A is a natural product research compound isolated from the fungus *Penicillium citrinum*. It is a carbon-bridged citrinin dimer formed by the coupling of citrinin and 2,3,4-trimethyl-5,7-dihydroxy-2,3-dihydrobenzofuran (TDDF) via a Diels-Alder reaction. In laboratory studies, penicitrinone A has demonstrated significant anti-inflammatory and antioxidant properties, including the inhibition of superoxide anion generation in human neutrophils (IC50 = 2.67 μM) and radical-scavenging activity against DPPH. While it has shown potential in vitro anticancer and antifungal activities, it is not currently being developed as a pharmaceutical drug by any company and lacks a defined molecular target.
Beyond the preview
Go deeper on penicitrinone A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on penicitrinone A.